Last reviewed · How we verify
Deproteinized bovine bone
Deproteinized bovine bone is a Biologic drug developed by University of Padova, School of Dental Medicine. It is currently in Phase 2 development.
Deproteinized bovine bone is used in dental procedures such as alveolar bone resorption, alveolar ridge augmentation, and periodontal diseases. It is classified as a hydrolytic enzyme modality, specifically a 2'-deoxyadenosine hydrolytic enzyme, which targets the molecular target 2'-deoxyadenosine.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Deproteinized bovine bone |
|---|---|
| Sponsor | University of Padova, School of Dental Medicine |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Is Cross-linked Hyaluronic Acid a Biologic Alternative for Alveolar Ridge Preservation? (NA)
- Radiographic and Histological Assessment of GBR Using DBB Compared to Spontaneous Bone Regeneration of Maxillary Defects , Resulted From Enucleation of Intra-bony Cystic Lesions (NA)
- Peri-Implant Hard and Soft Tissue Changes After Immediate Implant Placement With Socket Shield and Immediate Restoration Versus Early Implant Placement in the Esthetic Zone (NA)
- Collagenic vs Collagen-enriched Graft in Sinus Elevation: RCT (NA)
- Demineralized Bone Allograft Fibers Versus Particulate In Sinus Augmentation (NA)
- Immediate Implants in Front Teeth With Bone Loss: Regeneration and Temporary Crown in a Randomized Clinical Study (NA)
- Efficacy Of Eggshell-Derived Nanohydroxyapatite Based Mineralized Plasmatic Matrix Versus Xenogeneic Based Mineralized Plasmatic Matrix in Posterior Mandibular Socket Preservation (NA)
- Treatment of Complex Ridge Defects With Custom Meshes
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Deproteinized bovine bone CI brief — competitive landscape report
- Deproteinized bovine bone updates RSS · CI watch RSS
- University of Padova, School of Dental Medicine portfolio CI
Frequently asked questions about Deproteinized bovine bone
What is Deproteinized bovine bone?
Who makes Deproteinized bovine bone?
What development phase is Deproteinized bovine bone in?
Related
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing